Exchange: NASDAQ·Updated 04:26 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 06After Hours

Estimated EPS

-$0.54

Estimated Rev

$0M

$DFTX Q1 '26 Earnings Results & Recap Based on its current operating plan, Definium Therapeutics believes its cash, cash equivalents, and investments of $373.4M as of March 31, 2026, will sufficiently fund operations into 2028.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.54
--
--
N/A
Q1 '26
-$0.49
-$0.71
-44.27%
MISSED
Q4 '25
-$0.48
-$0.51
-5.44%
MISSED
Q3 '25
--
-$0.78
--
N/A

Advertisement|Remove ads.